4. Daunorubicine (liposome) in high risk GBM patients

A. Boiardi, A. Pozzi, G. Broggi, A. Salmaggi, A. Silvani

Research output: Contribution to journalArticlepeer-review


Daunorubicin encapsulated in liposomes is stable in the blood and may reach malignant glioma cells by leaking through the altered capillary walls of the tumor vasculature. The aim of the study was to evaluate the maximun tolerated dose and eventually the effectiveness in compassionate GBM patients. 14 rGBM pts with 2 months life expectancy, entered the study. All patients had already been given radiotherapy and repeated cycles of differentely combined chemotherapeutic drugs. Pts were sequentially enrolled in small groups, each treated at least two times with progressively increasing drug dosages. All patients or their relatives had signed consent. 3 pts received at least two times, daonoxome 60mg/sqm every 3 weeks; 4 pts 80 mg/sqm, 3 pts 100 mg/sqm and 4 pts 120 mg/sqm respectively. The delivery was continued until progressive disease occurred. Therefore two pts received 4 times 80 and 100 mg /sqm respectively, and another 3 times 1000mg/sqm, all being stable disease. Two out of four pts treated with 120mg/sqm showed grade 3° and 4° leukopenia and grade 3° thrombocytopenia after ten days. Thus the dose was reduced to 100mg/sqm for 2 other times; the 2 pts were 3 months SD. No haematological toxicity occurred until 100 mg/sqm dose. In 35,7% of cases the treatment was efficacious. The dose safety was 100 mg/sqm but we believe the dosage could be raised in pts previously untreated with chemotherapy.

Original languageEnglish
Pages (from-to)242
Number of pages1
JournalItalian Journal of Neurological Sciences
Issue number4
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of '4. Daunorubicine (liposome) in high risk GBM patients'. Together they form a unique fingerprint.

Cite this